Myasthenia Gravis Disease Market Research Report Information By Diagnosis (Imaging, Blood Tests, Electrodiagnostic, and Edrophonium Test), By Treatment (Medication, Surgery, and HSCT), By End-User (Hospitals, Clinics, and Academic Research Institutes), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2034

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Myasthenia Gravis Disease Market, by Diagnosis

6.1 Introduction

6.2 Imaging

6.2.1 Market Estimates & Forecast, 2023-2030

6.2.2 X-ray

6.2.2.1 Market Estimates & Forecast, 2023-2030

6.2.3 Computed Tomography (CT)

6.2.3.1 Market Estimates & Forecast, 2023-2030

6.2.3 Magnetic Resonance Imaging (MRI)

6.2.3.1 Market Estimates & Forecast, 2023-2030

6.2.3 Others

6.3 Blood Tests

6.3.1 Market Estimates & Forecast, 2023-2030

6.4 Electrodiagnostic

6.4.1 Market Estimates & Forecast, 2023-2030

6.5 Edrophonium Test

6.5.1 Market Estimates & Forecast, 2023-2030

6.6 Pulmonary Function Test

6.6.1 Market Estimates & Forecast, 2023-2030

6.7 Others

Chapter 7. Global Myasthenia Gravis Disease Market, by Treatment

7.1 Introduction

7.2 Medication

7.2.1 Market Estimates & Forecast, 2023-2030

7.2.2 Acetylcholinesterase Inhibitors

7.2.2.1 Market Estimates & Forecast, 2023-2030

7.2.2.2 Atropine

7.2.2.2.1 Market Estimates & Forecast, 2023-2030

7.2.2.3 Neostigmine

7.2.2.3.1 Market Estimates & Forecast, 2023-2030

7.2.2.4 Pyridostigmine.

7.2.2.4.1 Market Estimates & Forecast, 2023-2030

7.2.2.4 Others

7.2.3 Immunosuppressant Drugs

7.2.3.1 Market Estimates & Forecast, 2023-2030

7.2.3.2 Rituximab

7.2.3.2.1 Market Estimates & Forecast, 2023-2030

7.2.3.3 Azathioprine

7.2.3.3.1 Market Estimates & Forecast, 2023-2030

7.2.3.4 Mycophenolate Mofetil

7.2.3.4.1 Market Estimates & Forecast, 2023-2030

7.2.3.5 Tacrolimus.

7.2.3.5.1 Market Estimates & Forecast, 2023-2030

7.2.3.6 Others

7.2.4 Steroid

7.2.4.1 Market Estimates & Forecast, 2023-2030

7.2.4.2 Prednisone

7.2.4.2.1 Market Estimates & Forecast, 2023-2030

7.2.4.3 Others

7.2.5 Others

7.3 Surgery

7.3.1 Market Estimates & Forecast, 2023-2030

7.2.4 Thymectomy

7.2.4.1 Market Estimates & Forecast, 2023-2030

7.2.4 Others

7.4 Autologous. Hematopoietic Stem Cell Transplantation (HSCT)

7.4.1 Market Estimates & Forecast, 2023-2030

7.5 Plasmapheresis and Intravenous. Immunoglobulin

7.5.1 Market Estimates & Forecast, 2023-2030

7.6 Others

Chapter 8. Global Myasthenia Gravis Disease Market, by End-User

8.1 Introduction

8.2 Hospitals

8.2.1 Market Estimates & Forecast, 2023-2030

8.3 Clinics

8.3.1 Market Estimates & Forecast, 2023-2030

8.4 Academic Research Institutes

8.4.1 Market Estimates & Forecast, 2023-2030

8.4 Others

Chapter .9 Global Myasthenia Gravis Disease Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K.

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Valeant Pharmaceuticals International

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Sun Pharmaceuticals Industries Ltd

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Novartis Pharmaceuticals Corporation

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Teva Pharmaceutical Industries Ltd.

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Cipla Limited

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 F. Hoffmann Roche La Ltd.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Apotex Corporation

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Pfizer Inc.

11.8.1 Company Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Overview

11.8.4 Key Development

11.8.5 SWOT Analysis

11.9 Bristol-Myers and Company

11.9.1 Company Overview

11.9.2 Product Overview

11.9.3 Financial overview

11.9.4 Key Developments

11.10 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of the Pharmaceutical Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Myasthenia Gravis Disease Industry Synopsis, 2023-2030

Table 2 Myasthenia Gravis Disease Market Estimates & Forecast, 2023-2030, (USD Million)

Table 3 Myasthenia Gravis Disease Market, by Region, 2023-2030, (USD Million)

Table 4 Myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 5 Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 6 Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

Table 7 North America myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 8 North America Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 9 North America Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

Table 10 U.S. Myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 11 U.S. Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 12 U.S. Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

Table 13 Canada Myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 14 Canada Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 15 Canada Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

Table 16 South America Myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 17 South America Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 18 South America Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

Table 19 Europe Myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 20 Europe Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 21 Europe Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

Table 22 Western Europe Myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 23 Western Europe Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 24 Western Europe Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

Table 25 Eastern Europe Myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 26 Eastern Europe Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 27 Eastern Europe Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

Table 28 Asia Pacific Myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 29 Asia Pacific Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 30 Asia Pacific Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

Table 31 Middle East & Africa Myasthenia Gravis Disease Market, by Diagnosis, 2023-2030, (USD Million)

Table 32 Middle East & Africa Myasthenia Gravis Disease Market, by Treatment, 2023-2030, (USD Million)

Table 33 Middle East & Africa Myasthenia Gravis Disease Market, by End-User, 2023-2030, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Myasthenia Gravis Disease Market

Figure 3 Segmentation Market Dynamics for the Myasthenia Gravis Disease Market

Figure 4 Global Myasthenia Gravis Disease Market Share, by Diagnosis 2020

Figure 5 Global Myasthenia Gravis Disease Market Share, by Treatment 2020

Figure 6 Global Myasthenia Gravis Disease Market Share, by End-User, 2020

Figure 7 Global Myasthenia Gravis Disease Market Share, by Region, 2020

Figure 8 North America Myasthenia Gravis Disease Market Share, by Country, 2020

Figure 9 Europe Myasthenia Gravis Disease Market Share, by Country, 2020

Figure 10 Asia Pacific Myasthenia Gravis Disease Market Share, by Country, 2020

Figure 11 Middle East & Africa Myasthenia Gravis Disease Market Share, by Country, 2020

Figure 12 Global Myasthenia Gravis Disease Market: Company Share Analysis, 2020 (%)

Figure 13 Valeant Pharmaceuticals International: Key Financials

Figure 14 Valeant Pharmaceuticals International: Segmental Revenue

Figure 15 Valeant Pharmaceuticals International: Geographical Revenue

Figure 16 Sun Pharmaceuticals Industries Ltd: Key Financials

Figure 17 Sun Pharmaceuticals Industries Ltd: Segmental Revenue

Figure 18 Sun Pharmaceuticals Industries Ltd: Geographical Revenue

Figure 19 Novartis Pharmaceuticals Corporation: Key Financials

Figure 20 Novartis Pharmaceuticals Corporation: Segmental Revenue

Figure 21 Novartis Pharmaceuticals Corporation: Geographical Revenue

Figure 22 Circle Cardiovascular Imaging Inc: Key Financials

Figure 23 Circle Cardiovascular Imaging Inc: Segmental Revenue

Figure 24 Circle Cardiovascular Imaging Inc: Geographical Revenue

Figure 25 Cipla Limited: Key Financials

Figure 26 Cipla Limited: Segmental Revenue

Figure 27 Cipla Limited: Geographical Revenue

Figure 28 F. Hoffmann Roche La Ltd.: Key Financials

Figure 29 F. Hoffmann Roche La Ltd.: Segmental Revenue

Figure 30 F. Hoffmann Roche La Ltd.: Geographical Revenue

Figure 31 Apotex Corporation: Key Financials

Figure 32 Apotex Corporation: Segmental Revenue

Figure 33 Apotex Corporation: Geographical Revenue

Figure 34 Pfizer Inc.: Key Financials

Figure 35 Pfizer Inc.: Segmental Revenue

Figure 36 Pfizer Inc.: Geographical Revenue

Figure 37 Bristol-Myers and Company: Key Financials

Figure 38 Bristol-Myers and Company: Segmental Revenue

Figure 39 Bristol-Myers and Company: Geographical Revenue